Core Insights - The core theme of the conference was "Collaborative Win-Win: Smartly Leading the Future," focusing on enhancing chronic disease management through artificial intelligence [1][2] - A strategic partnership was formed between Fangzhou Jianke and Suzhou Wangshan Wangshui Biopharmaceutical Co., Ltd., aimed at integrating core industry resources with digital technology capabilities [1][5] Industry Trends - The Chinese government has emphasized the importance of "AI+" in various sectors, particularly in healthcare, as outlined in the recent policy documents [2] - The aging population and the increasing prevalence of chronic diseases in China present significant opportunities for AI applications in healthcare [2] Company Developments - Fangzhou Jianke's CEO, Xie Fangmin, highlighted the company's commitment to solving real problems in chronic disease management through AI technology [2][4] - The company reported a 2.4 times increase in users experiencing AI features in October compared to September, with a 50% increase in Gross Merchandise Volume (GMV) [4] Strategic Collaboration - The partnership between Fangzhou Jianke and Wangshan Wangshui aims to break down industry barriers and enhance the entire health service chain from drug supply to health services [5][6] - Both companies plan to leverage their respective strengths to create a customer-centric health service system, providing comprehensive health management solutions [5][6] Future Outlook - The collaboration is expected to facilitate a more efficient connection between biopharmaceutical research and health services, ensuring that research outcomes meet user needs [6] - Fangzhou Jianke aims to continue its focus on chronic disease management and enhance its technological foundation to drive digital upgrades in health services [6]
从峰会到共赢！方舟健客、旺山旺水深化“AI+慢病管理”领域战略合作，共筑健康产业数智未来